Previous Close | 60.60 |
Open | 60.49 |
Bid | 43.38 x 200 |
Ask | 77.31 x 200 |
Day's Range | 59.75 - 60.86 |
52 Week Range | 25.98 - 110.25 |
Volume | |
Avg. Volume | 1,929,620 |
Market Cap | 6.315B |
Beta (5Y Monthly) | 0.72 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Cytokinetics said Monday its drug "significantly" improved exercise capacity in HCM patients. On Tuesday, Cytokinetics stock reversed higher.
Deep Dive into Financials and Strategic Developments
Cytokinetics ( NASDAQ:CYTK ) First Quarter 2024 Results Key Financial Results Net loss: US$135.6m (loss widened by 3.3...